Clinical Trials
The Tumor Immunotherapy Program has a number of studies that are currently recruiting patients. For information about how to be referred to one of these studies, please contact us.
Currently Recruiting
-
TILs-001-DC
A Phase I Study Evaluating the Feasibility and Safety of Infusion of Re-StimulatedAutologous Tumor-Infiltrating Lymphocytes (TILs) Followed by Low-Dose Interleukin-2 Therapy in Patients with Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Learn more(opens information in a pop-up overlay)TILs-001-DC
A Phase I Study Evaluating the Feasibility and Safety of Infusion of Re-StimulatedAutologous Tumor-Infiltrating Lymphocytes (TILs) Followed by Low-Dose Interleukin-2 Therapy in Patients with Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Eligible tumor type: Ovarian Cancer
Sponsor: In-house
PI: Marcus Butler
NCT#: NCT01883297
For more information visit https://clinicaltrials.gov/ct2/show/NCT01883297
-
TILs-002-MEL
Phase II Study Evaluating the Infusion Of Autologous Tumor-Infiltrating Lymphocytes (TILs) And Low-Dose Interleukin-2 (IL-2) Therapy Following A Preparative Regimen Of Non-Myeloablative Lymphodepletion Using Cyclophosphamide And Fludarabine In Patients With Metastatic Melanoma
Learn more(opens information in a pop-up overlay)TILs-002-MEL
Phase II Study Evaluating the Infusion Of Autologous Tumor-Infiltrating Lymphocytes (TILs) And Low-Dose Interleukin-2 (IL-2) Therapy Following A Preparative Regimen Of Non-Myeloablative Lymphodepletion Using Cyclophosphamide And Fludarabine In Patients With Metastatic Melanoma
Eligible tumor type: Metastatic Melanoma
Sponsor: In-house
PI: Marcus Butler
NCT#: NCT01883323
For more information visit https://clinicaltrials.gov/ct2/show/NCT01883323?term=TILs-002-MEL&rank=1
-
TILs-003-Meso
Phase I/II study evaluating the infusion of tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with malignant pleural mesothelioma
Learn more(opens information in a pop-up overlay)TILs-003-Meso
Phase I/II study evaluating the infusion of tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with malignant pleural mesothelioma)
Eligible tumor types: malignant pleural mesothelioma
Sponsor: In-house
PI: Marcus Butler
NCT#: NCT02414945
For more information visit https://clinicaltrials.gov/ct2/show/NCT02414945?term=TILs-003-Meso&rank=1
-
METADUR
An open-label, phase II basket study of a hypomethylating agent azacitidine and durvalumab (anti-PDL1) in advanced solid tumors.
Learn more(opens information in a pop-up overlay)METADUR
An open-label, phase II basket study of a hypomethylating agent azacitidine and durvalumab (anti-PDL1) in advanced solid tumors
Eligible tumor types: Breast Cancer, Colorectal Cancer, Ovarian Cancer
Sponsor: In-house
PI: Lillian Siu
NCT#: TBD
-
INSPIRE
INvestigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
Learn more(opens information in a pop-up overlay)INSPIRE
INvestigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
Eligible tumor types: metastatic melanoma, triple negative breast cancer, squamous cell cancer of the head and neck, ovarian cancer, solid cancers
Sponsor: In-house
PI: Lillian Siu
NCT#: NCT02644369
For more information visit https://clinicaltrials.gov/ct2/show/NCT02644369
-
1301-02
Phase 1b Study of NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes in Patients with Solid Tumors
Learn more(opens information in a pop-up overlay)1301-02
Phase 1b Study of NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes in Patients with Solid Tumors
Eligible tumor types:Solid Cancer
Sponsor: In-house (in collaboration with Takara Bio Inc)
PI: Marcus Butler
NCT#: 02869217
For more information visit https://clinicaltrials.gov/ct2/show/NCT02869217
Recruiting Soon
-
ACTIVATE
Phase Ib trial of pembrolizumab administered in combination or following adoptive cell therapy: A multiple cohort study
Learn more(opens information in a pop-up overlay)ACTIVATE
Phase Ib trial of pembrolizumab administered in combination or following adoptive cell therapy: A multiple cohort study
Eligible tumor types: ovarian cancer, metastatic melanoma
Sponsor: In-house
PI: Marcus Butler
NCT#: TBD
-
MG1MA3 with AdMA3
A phase Ib study of MG1 MARABA/MAGE-A3 (MG1MA3) with adenovirus vaccine/MAGE A3 (AdMA3) in combination with the immune checkpoint inhibitor Pembrolizumab in patients with incurable advanced or metastatic MAGE-A3 expressing solid tumors
Learn more(opens information in a pop-up overlay)MG1MA3 with AdMA3
A phase Ib study of MG1 MARABA/MAGE-A3 (MG1MA3) with adenovirus vaccine/MAGE A3 (AdMA3) in combination with the immune checkpoint inhibitor Pembrolizumab in patients with incurable advanced or metastatic MAGE-A3 expressing solid tumors
Eligible tumor types: Incurable advanced or metastatic MAGE-A3 expressing solid tumors
Sponsor: In-house
PI: Marcus Butler
NCT#: TBD
-
Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering
This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.
This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.
Learn more(opens information in a pop-up overlay)Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering
This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.
This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.
Eligible Tumor Type: acute myeloid leukemia (AML)
Sponsor: In-house
PI: Dr. Mark Minden
NCT#: NCT02483312
For more information visit https://clinicaltrials.gov/ct2/show/NCT02483312